Bioavailability of Intranasal vs. Rectal Diazepam

Epilepsy Research

Volumn 103, Issue 2-3, 2013, Pages 254-261

  Ivaturi, Vijay ^a,b   Kriel, Robert ^a,b   Brundage, Richard ^a,b   Loewen, Gordon ^c   Mansbach, Hank ^c   Cloyd, James ^a,b  

^a Center for Orphan Drug Research   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c Valeant Pharmaceuticals   (United States)

Author keywords

Diazepam; Intranasal; Seizure emergencies

Indexed keywords

ACUDIAL; DIAZEPAM; UNCLASSIFIED DRUG;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DOSAGE FORM COMPARISON; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; NOSE IRRITATION; PAIN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; SCORING SYSTEM; SEDATION; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; VISUAL ANALOG SCALE;

ADMINISTRATION, INTRANASAL; ADMINISTRATION, RECTAL; ADOLESCENT; ADULT; AGED; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; CROSS-OVER STUDIES; DIAZEPAM; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PAIN MEASUREMENT;

EID: 84873078098     PISSN: 09201211     EISSN: 18726844     Source Type: Journal    
DOI: 10.1016/j.eplepsyres.2012.07.018     Document Type: Article

References (12)

1. Brown L., Bergen D.C., Kotagal P., Groves L., Carson D. Safety of Diastat when given at larger-than-recommended doses for acute repetitive seizures. Neurology 2001, 56:1112.
2. Cloyd J. Pharmacologic considerations in the treatment of repetitive or prolonged seizures. J. Child Neurol. 2007, 22:47S-52S.
3. Cloyd J.C., Lalonde R.L., Beniak T.E., Novack G.D. A single-blind, crossover comparison of the pharmacokinetics and cognitive effects of a new diazepam rectal gel with intravenous diazepam. Epilepsia 1998, 39:520-526.
4. Ivaturi V.D., Riss J.R., Kriel R.L., Cloyd J.C. Pharmacokinetics and tolerability of intranasal diazepam and midazolam in healthy adult volunteers. Acta Neurol. Scand. 2009, 120:353-357.
5. Ivaturi V.D., Riss J.R., Kriel R.L., Siegel R.A., Cloyd J.C. Bioavailability and tolerability of intranasal diazepam in healthy adult volunteers. Epilepsy Res. 2009, 84:120-126.
6. Kaplan S.A., Jack M.L., Alexander K., Weinfeld R.E. Pharmacokinetic profile of diazepam in man following single intravenous and oral and chronic oral administrations. J. Pharm. Sci. 1973, 62:1789-1796.
7. Milligan N., Dhillon S., Oxley J., Richens A. Absorption of diazepam from the rectum and its effect on interictal spikes in the EEG. Epilepsia 1982, 23:323-331.
8. Mitchell W.G., Conry J.A., Crumrine P.K., Kriel R.L., Cereghino J.J., Groves L., Rosenfeld W.E. An open-label study of repeated use of diazepam rectal gel (Diastat) for episodes of acute breakthrough seizures and clusters: safety, efficacy, and tolerance. North American Diastat Group. Epilepsia 1999, 40:1610-1617.
9. Pellock J.M. Safety of Diastat, a rectal gel formulation of diazepam for acute seizure treatment. Drug Saf. 2004, 27:383-392.
10. Schmidt D. Benzodiazepines: diazepam. Antiepileptic Drugs 1995, 705-724. Raven Press, New York. R.H. Levy, R.H. Mattson, B.S. Meldrum (Eds.).
11. Scott J., Huskisson E.C. Graphic representation of pain. Pain 1976, 2:175-184.
12. Wermeling D.P. Intranasal delivery of antiepileptic medications for treatment of seizures. Neurotherapeutics 2009, 6:352-358.